PMC:4822111 / 5062-5407 JSONTXT

{"project":"2_test","denotations":[{"id":"27066091-20679609-56335776","span":{"begin":242,"end":244},"obj":"20679609"},{"id":"27066091-19349550-56335777","span":{"begin":242,"end":246},"obj":"19349550"},{"id":"27066091-21989327-56335778","span":{"begin":242,"end":248},"obj":"21989327"}],"text":"Eribulin phase II trials\nThe efficacy and safety of eribulin (1.4 mg/m2 on day 1 and day 8 of a 21-day cycle) have been evaluated in three phase II studies in patients with LABC or mBC pretreated with an anthracycline and a taxane (Table 2) [181920]. In these studies, eribulin demonstrated antitumor activity with a manageable toxicity profile."}